KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Change in Receivables (2016 - 2020)

Thermo Fisher Scientific's Change in Receivables history spans 12 years, with the latest figure at $444.0 million for Q4 2020.

  • For the quarter ending Q4 2020, Change in Receivables rose 562.5% year-over-year to $444.0 million, compared with a TTM value of $1.3 billion through Dec 2020, up 478.67%, and an annual FY2025 reading of $426.0 million, up 149.12% over the prior year.
  • Change in Receivables for Q4 2020 was $444.0 million at Thermo Fisher Scientific, down from $663.0 million in the prior quarter.
  • The five-year high for Change in Receivables was $663.0 million in Q3 2020, with the low at -$96.0 million in Q4 2019.
  • Average Change in Receivables over 5 years is $130.4 million, with a median of $49.6 million recorded in 2016.
  • Year-over-year, Change in Receivables surged 7629.03% in 2016 and then crashed 230.77% in 2019.
  • Tracing TMO's Change in Receivables over 5 years: stood at $239.6 million in 2016, then dropped by 16.11% to $201.0 million in 2017, then surged by 50.25% to $302.0 million in 2018, then tumbled by 131.79% to -$96.0 million in 2019, then soared by 562.5% to $444.0 million in 2020.
  • Per Business Quant, the three most recent readings for TMO's Change in Receivables are $444.0 million (Q4 2020), $663.0 million (Q3 2020), and -$23.0 million (Q2 2020).